Allocations
Venture capital and small business finance firm Advantage Capital Partners has been awarded a USD80 million allocation in the highly competitive federal New Markets Tax Credit program. This latest allocation brings the firm’s total awards since the program began in 2002 to USD524 million.
Through prior state and federal New Markets program allocations, Advantage Capital has invested more than USD650 million in private capital into 147 businesses, which, in the aggregate, employ more than 8,000 people and have attracted more than USD900 million in follow-on capital to support their growth.
Announcing the New Markets Tax Credit (NMTC) program allocation awards
Catella has acted as adviser and arranger for Sefyr Värme AB, the parent company of the district heating company Värmevärden AB, in the issue of a senior secured note in excess of SEK 900 million, directed at selected Nordic institutional investors. The bond carries a 7% coupon and has a tenor of five years.


“This is the first major transaction resulting from Catella’s endeavours within the financing area. We see clearly that companies nowadays have a major need for alternatives to traditional bank financing,” says Johan Ericsson, CEO Catella AB.


“We are witnessing strong interest in the corporate bond market
Halfpenny Technologies has secured USD2.25 million in venture capital funding co-led by Connecticut-based Vital Financial and Philadelphia-based Emerald Stage2 Ventures. Existing investors including Pennsylvania-based Osage Venture Partners, New York-based Milestone Venture Partners, and LORE Associates, a Philadelphia-based angel, also participated in the round.
"We are very pleased to have the backing of investors who share our vision of delivering innovative clinical data integration solutions to hospitals, laboratories, and payors," says Tim Kowalski, CEO of Halfpenny Technologies. "This round of financing positions the company to provide its Lab Hub platform to a broader range of clients."
The Lab Hub platform enables
Agribusiness and food company Bunge Limited is to acquire Climate Change Capital Limited (CCCG), a UK-regulated sustainable asset manager and advisor.


The transaction was approved by the UK’s Financial Services Authority (FSA) on 20 February, 2012, and CCCG has obtained the required shareholder approvals to proceed. The transaction is expected to close in the coming weeks; financial terms will not be disclosed.


Daniel Rudolph, Managing Director, Bunge Financial Services Group, says: "Bunge’s Financial Services Group has been active in carbon markets since their inception, both as a buyer of carbon credits and an advisor to other market participants. The transaction
Blackstar has entered into a conditional agreement for the sale of 72,989,078 ordinary shares in Litha Healthcare Group Limited to Paladin Labs Inc. The Disposal, for a cash consideration of GBP16.6 million, represents 50% of Blackstar’s interest in Litha and equates to ZAR2.75 per Litha share.
On completion, the Disposal proceeds will represent a 4.58 times return on investment in South African Rand and 5.36 times return in Pounds Sterling, which equates to a 32% IRR and 36% IRR, respectively, over the five year holding period. The Disposal proceeds will be applied against the Investec Bank Limited debt facility that
High Road Capital Partners’ portfolio company Advanced Sleep Medicine Services, Inc has completed the acquisition of Pacific Sleep Medicine Services, a provider of sleep disorder diagnostic services with laboratory facilities throughout Southern California. The acquisition closed on 17 February, 2012.
Pacific Sleep will become part of Advanced Sleep’s existing network of California-based sleep disorder diagnostic facilities.Advanced Sleep was acquired by High Road in May 2010.
“The addition of Pacific Sleep’s facilities is part of our overall strategy to expand Advanced Sleep’s presence throughout California both organically and through acquisitions,” says Bill Connell (pictured), the High Road Partner who led
Ceptaris Therapeutics, Inc, a privately held specialty pharmaceutical company, has secured USD15 million in venture debt financing from Silicon Valley Bank and Oxford Finance.
The New Drug Application (NDA) for Ceptaris’ drug candidate, mechlorethamine gel, is currently undergoing review by the US Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
Ceptaris received USD7.5 million at closing and has access to the remaining USD7.5 million if the NDA is approved by the FDA. The funding will be used for ongoing operational expenses and preparation for commercialization of
A record number of private equity add-on deals were completed in 2011 and the upward turn in transactions of this type is continuing into 2012, according to date released by Preqin.
While the number of deals of other types plummeted, the number of add-on deals completed during the downturn remained relatively consistent and has since more than doubled.
In January 2012, add-ons accounted for 35% of all completed deals, an increase from 2008/2009 when around a quarter of deals were of this type. Add-ons are generally small and mid-sized deals, so it is perhaps unsurprising that there has been a
Advent International and GS Capital Partners VI Fund, LP and certain of its affiliates have signed a definitive merger agreement to acquire TransUnion from its current stockholders, including Madison Dearborn Partners and the Pritzker family business interests.
The transaction, which is expected to close late first quarter or early second quarter of 2012, values TransUnion at over USD3 billion. TransUnion President and Chief Executive Officer Bobby Mehta and the rest of the company’s leadership team will remain with TransUnion.
“Since we spun TransUnion out of the Marmon Group we have extended the global footprint into more than a dozen countries
Capital Dynamics has held the final closing of Capital Dynamics Champion Ventures VII, a US-based venture program targeting top-tier US venture managers or pre-eminent international venture firms with strong US ties.
The final closing of Capital Dynamics Champion Ventures VII ends a successful fundraising for CapitalDynamics’ US-based venture capital program with a total of USD 111 million in committed capital. The program has already made several venture fund commitments. Many of these funds have commenced investing andsome of the funds have already experienced IPOs of underlying portfolio companies.
Capital Dynamics Champion Ventures VII builds on Capital Dynamics’ established network of
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
